Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 17/20 | 0.68 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.51 |
| ▸ | CTSD | P07339 | 3/20 | 0.50 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25916649 | 0.90 | BACE1 (0.84) | BACE1BACE2CTSDAPPGAA | |
| SCHEMBL25916645 | 0.90 | BACE1 (0.84) | BACE1BACE2CTSDAPPGAA | |
| SCHEMBL14136382 | 0.86 | BACE1 (0.82) | BACE1BACE2CTSDAPP | |
| SCHEMBL5050381 | 0.85 | BACE1 (0.69) | BACE1BACE2CTSDAPPKMT2A | |
| SCHEMBL5049151 | 0.84 | BACE1 (0.65) | BACE1BACE2CTSDAPP | |
| SCHEMBL5050489 | 0.83 | BACE1 (0.62) | BACE1BACE2CTSDAPP | |
| SCHEMBL8269001 | 0.83 | BACE1 (0.59) | BACE1BACE2CTSDAPP | |
| SCHEMBL5053690 | 0.83 | BACE1 (0.59) | BACE1BACE2CTSDAPP | |
| SCHEMBL5055360 | 0.82 | BACE1 (0.59) | BACE1BACE2CTSDAPP | |
| SCHEMBL5055396 | 0.82 | BACE1 (0.57) | BACE1BACE2CTSDAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207527-A1 | Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof | COMENTIS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207527-A1 | Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof | BACE1, BACE2, PSEN1 | BACE1 1/4885BACE2 2/4885CTSD 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.